Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Developmental Biology Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GATA6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GATA6 Recombinant Protein / Zinc Finger Domain High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View GATA6 Products |
| Gene Delivery | GATA6 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View GATA6 Products |
| Benchmark Ab | Anti-GATA6 Recombinant Antibody Recombinant positive control for IHC, Western Blot, and ChIP. |
View GATA6 Products |
| Validator | GATA6 siRNA Set For knockdown verification. |
View GATA6 Products |
| Related Target A | GATA4 Subfamily member required for off-target counter-screening to avoid cardiac toxicity. |
View GATA4 Products |
| Related Target B | KRAS Synergistic oncogenic driver co-amplified in pancreatic ductal adenocarcinoma (PDAC). |
View KRAS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nuclear localization & DNA-binding complexity | High-purity DNA-binding domain (Zinc Finger) proteins available with >95% purity |
| GATA subfamily off-target screening (GATA4/5) | Homolog panel proteins strictly verified by mass spectrometry |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live GATA6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GATA6 therapeutics is intensifying, with major players shifting focus from traditional diagnostics to novel targeting modalities. As an intracellular zinc-finger transcription factor, GATA6 has historically been deemed "undruggable." However, the next wave of R&D is targeting GATA6 via PROTACs (proteolysis targeting chimeras), molecular glues, and RNA therapeutics (siRNA/ASO) to address highly aggressive solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC) and gastric cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Molecular Glue | Academic Consortia, Biotech Startups | Pancreatic Cancer (PDAC), Gastric Cancer | Degradation Kinetics Assay (Need Lentivirus for Stable Cell Line construction) |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Refractory Solid Tumors | Knockdown Validation (Need sequence-verified siRNA & qPCR controls) |
| Small Molecule Inhibitors | Oncology Discovery Teams | Colorectal Cancer, Barrett's Esophagus | Selectivity Assay (Need GATA4/GATA5 vs GATA6 Recombinant Proteins) |